Related Experiment Videos
Pulmonary metastatectomy for soft tissue sarcomas: is it valuable?
1Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
The Journal of Cardiovascular Surgery
|November 8, 2001
Summary
Pulmonary metastatectomy for soft tissue sarcoma (STS) lung metastases is a viable treatment. Complete resection is key, with disease-free intervals over six months and fewer metastases showing better survival trends.
Area of Science:
- Oncology
- Thoracic Surgery
- Sarcoma Research
Background:
- Pulmonary metastases from soft tissue sarcomas (STS) present a significant challenge.
- Determining the efficacy and prognostic factors of surgical resection for these metastases is crucial.
Purpose of the Study:
- To evaluate the value and benefit of pulmonary metastatectomy for STS.
- To identify factors predicting prognosis after surgical resection of lung metastases.
Main Methods:
- Retrospective analysis of 23 patients with STS lung metastases undergoing resection.
- Surgical approaches included lateral thoracotomy and median sternotomy.
- Pulmonary resections involved wedge resections, segmentectomies, and lobectomies.
Main Results:
- Five-year overall and disease-free survival rates were 24% and 21%, respectively.
- Prognostic factors like age, sex, histology, tumor grade, size, laterality, resection type, and chemotherapy did not significantly impact survival.
- A trend towards improved survival was observed in patients with a disease-free interval >6 months and ≤3 metastases.
Conclusions:
- Surgical excision of lung metastases from STS is a well-accepted first-line treatment when complete resection is feasible.
- Further research is required to establish the role of adjuvant chemotherapy.